[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599851":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":54,"collaborators":57,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":25,"eligibilityCriteria":79,"healthyVolunteers":75,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":25,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":25,"overallStatus":38,"whyStopped":25,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Beijing Tiantan Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Indobufen+clopidogrel group","EXPERIMENTAL","Patients in the experimental group will be required to take indobufen (100 mg twice daily) + clopidogrel (75 mg once daily) starting 5 days before the procedure and continuing until 180 days postoperatively.",[13],"Drug: Indobufen treatment",{"label":15,"type":16,"description":17,"interventionNames":18},"Aspirin+clopidogrel group","ACTIVE_COMPARATOR","Patients in the control group will be required to take aspirin (100 mg once daily) + clopidogrel (75 mg once daily) starting 5 days before the procedure and continuing until 180 days postoperatively.",[19],"Drug: Aspirin treatment",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","Indobufen treatment",[9],null,{"type":22,"name":27,"description":17,"armGroupLabels":28,"otherNames":25},"Aspirin treatment",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Qingyuan Liu, M.D.","CONTACT","+86-13260457220","13260457220@163.com",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":25,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Capital Medical University Affiliated Beijing Tiantan Hospital","RECRUITING","Beijing","Beijing Municipality","China","CN",{"type":44,"coordinates":45},"Point",[46,47],116.39723,39.9075,{"lat":47,"lon":46},[50,51],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},{"name":52,"role":53,"phone":25,"phoneExt":25,"email":25},"Shuo Wang, M.D.","PRINCIPAL_INVESTIGATOR",{"type":53,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Wang Shuo","Director of Department of Cerebrovascular Neurosurgery",[58,60,62,65,67,69,71],{"name":59,"class":6},"RenJi Hospital",{"name":61,"class":6},"First Affiliated Hospital of Fujian Medical University",{"name":63,"class":64},"Jiangnan University Central Hospital","UNKNOWN",{"name":66,"class":6},"Beijing Chao Yang Hospital",{"name":68,"class":6},"Beijing Friendship Hospital",{"name":70,"class":6},"Beijing Shuyi Hospital",{"name":72,"class":6},"The Central Hospital of Lishui City","100599851","indobufen-versus-aspirin-in-endovascular-unruptured-intracranial-aneurysms-treatment-input-100599851",false,"NCT07089862","INdobufen Versus asPirin in Endovascular Unruptured Intracranial Aneurysms Treatment (INPUT)","Indobufen Versus Aspirin in Endovascular Unruptured Intracranial Aneurysms Treatment","Inclusion Criteria:\n\n1. Age 18-75 years (male or female);\n2. Radiologically confirmed saccular intracranial aneurysm (by specialist assessment);\n3. Scheduled for endovascular embolization (including: coil embolization with stent assistance or flow diversion);\n4. Signed informed consent obtained.\n\nExclusion Criteria:\n\n1. Concomitant vascular malformations, tumors, abscesses or other cerebral diseases such as multiple sclerosis;\n2. Major surgery within 30 days prior to enrollment including fracture surgery or hip replacement;\n3. History of ischemic stroke, ischemic heart disease or hemorrhagic disorders including intracranial hemorrhage, gastrointestinal bleeding, fundus hemorrhage or unexplained bleeding within the past 6 months;\n4. Planned elective surgery within 3 months after the procedure;\n5. Any hematologic disorders or inherited coagulation abnormalities;\n6. Severe renal or hepatic dysfunction;\n7. History of hemostatic disorders, systemic bleeding, thrombocytopenia or neutropenia;\n8. History of symptomatic non-traumatic intracranial hemorrhage or cerebral amyloid angiopathy;\n9. Severe cardiopulmonary diseases considered by investigators to be unsuitable for the study;\n10. Women of childbearing potential with negative pregnancy test but refusing contraceptive measures, or those who are pregnant or lactating;\n11. Current participation in other investigational drug or device trials.\n\nWithdrawal Criteria:\n\n1. Receiving aneurysm treatment other than coil embolization with stent assistance or flow diversion;\n2. Occurrence of endpoint events during stent-assisted aneurysm embolization procedure (as adjudicated by the Clinical Events Committee), including procedure-related hemorrhagic events (aneurysm rupture, parent artery rupture, subarachnoid hemorrhage, acute ipsilateral intracerebral hemorrhage, and acute ipsilateral subdural\u002Fepidural hematoma) or ischemic events (acute large vessel occlusion, in-stent thrombosis, and diffuse ipsilateral vascular infarction caused by plaque dislodgement);\n3. Device-related quality issues during stent-assisted embolization, including stent problems (stent fracture, failure to deploy properly, incomplete expansion due to product defect) and coil problems (premature detachment before intentional deployment, coil unraveling, and failure to detach);\n4. Postoperative life expectancy \\\u003C3 months;\n5. Inability to complete 5-day premedication due to emergency surgery or other reasons;\n6. Intolerance to oral antiplatelet therapy due to allergy or other contraindications.","ALL","18 Years","75 Years",{"count":84,"type":85},2500,"ESTIMATED","INTERVENTIONAL",[88],"NA","This project aims to evaluate the safety and efficacy of the antiplatelet regimen combining indobufen and clopidogrel in preventing ischemic events after stent-assisted coiling embolization and flow diverter implantation for intracranial aneurysms.\n\nUsing a randomization system, patients with unruptured intracranial aneurysms scheduled for interventional treatment will be divided into an experimental group and a control group. Patients in the experimental group will be required to take indobufen (100 mg twice daily) + clopidogrel (75 mg once daily) starting 5 days before the procedure and continuing until 180 days postoperatively. Patients in the control group will be required to take aspirin (100 mg once daily) + clopidogrel (75 mg once daily) starting 5 days before the procedure and continuing until 180 days postoperatively.\n\nAn independent group of researchers will assess cerebrovascular thromboembolic events and bleeding events at different time points.",[91,92],"Unruptured Intracranial Aneurysm","Indobufen","2026-03-13",{"date":95,"type":96},"2026-03-16","ACTUAL",{"date":98,"type":96},"2025-08-31",{"date":100,"type":85},"2026-12-31",{"name":5,"class":6},1]